Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0642-1895 in Healthy Adults
NCT07829406Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial comparing NNC0642-1895 with Placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events. Started Sep 2026; status: recruiting.
02
Drugs
NNC0642-1895
Beyond the preview
Go deeper on NCT07829406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07829406.